Aloe, L, Vinciguerra, M, Tonchev, AB, Fiore, M, Deleva, N, Frohlich, J and Chaldakov, GN (2021) A Growing Journey From Neurotrophins To Metabotrophins In Cardiometabolic Diseases. Adipobiology, 11. pp. 5-9. ISSN 1313-3705

Preview

Text A GROWING JOURNEY FROM NEUROTROPHINS In Cardiometabolic Diseases.pdf - Published Version Available under License Creative Commons Attribution. Download (222kB) | Preview

Abstract

Currently, obesity has been recognized as a prime risk in the development of cardiometabolic diseases (CMD) and neurodegenerative diseases (NDD). The pathogenesis and therapy of CMD are immensely complex at the cellular and molecular levels. This scenario raises the question of how such a complexity may be grappledin a more tangible manner. Since 2003, we have been thinking “what nobody has yet thought about that everybody sees”, namely, matabotrophic factors (MTF, metabotrophins). The latter include mainly (i) the neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), and (ii) the adipomyokines adiponectin, irisin, BDNF, fibroblast growth factor-21 alike as adipose- and skeletal muscle-derived signaling proteins (these latter discussed in another review in the present volume of Adipobiology). Herein, we argue that obesity and related CMD and NDD, particularly Alzheimer’s disease, may be viewed as MTF-deficient diseases. Further studies on MTF signatures and ramifications in these diseases are required. These would provide greater insights on how we can make MTF work for the improvement of physiological and psychological quality of human life.

Item Type:	Article
Subjects:	R Medicine > RS Pharmacy and materia medica
Divisions:	Pharmacy and Biomolecular Sciences
Publisher:	Medical niversity Press, Varna, Bulgaria on behalf of the Bulgarian Society for Cell Biology
SWORD Depositor:	A Symplectic
Date Deposited:	05 Mar 2025 16:43
Last Modified:	05 Mar 2025 16:45
DOI or ID number:	10.14748/adipo.v11.8558
URI:	https://researchonline.ljmu.ac.uk/id/eprint/25798

View Item